Investor presentation for the quarter and half year ended September 30, 2026.

Date: November 02, 2026 Manager, Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 533315 Dear Sir/Madam, Sub: Investor Presentation With reference to the subject, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2026. Kindly take the above information on record. Thanking You, Yours faithfully, For Innovassynth Technologies (India) Limited (Formerly known as Innovassynth Investments Limited) Sameer Pakhali Company Secretary & Compliance Officer ACS 55746 Innovassynth Technologies (India) Limited (Formerly, Innovassynth Investments Limited) Registered office: Corporate Office: Old Mumbai–Pune Road, TCG International Biotech Park, Khopoli – 410 203, India. 2nd Floor, Genesis Square, Phone: +91–2192–260100 Hinjewadi Phase – II, Email: itil@innovassynth.com Pune – 411 057, India. CIN: L67120MH2008PLC178923 Phone: +91–20–61921000 www.innovassynth.com IInnvveessttoorr PPrreesseennttaattiioonn QQ22FFYY2277 22--NNoovveemmbbeerr--22002266 Disclaimer “This presentation has been prepared by Innovassynth Technologies India Limited (“Company”) (formerly known as Innovassynth Investments Limited). The presentation aims to cover key financial and business highlights. This presentation and some statements herein may be forward-looking statements and may not be based on historical information or facts and may be expressed in good faith and in the Company’s management’s opinion reasonable, including those relating to the Company’s general business plans and strategy, its growth prospects and its competitive and regulatory environment. These statements are inherently subject to a variety of risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected based on risks relating to the execution, global supply chain, technological developments, geopolitical developments, etc.. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. This presentation does not aim to offer, and should not be viewed as providing, a complete or comprehensive assessment of the Company’s business, financial performance, operating results, market position, or prospects. Furthermore, this presentation is not an offer, solicitation, or invitation to buy or subscribe for any securities of the Company.” Executive Summary and Financials Executive Summary Performance Update and Outlook • EBITDA was impacted primarily by the spillover of certain sales scheduled for Q2 into the subsequent quarter and, to some extent, by higher costs of certain raw materials due to geopolitical developments in West Asia. • Given the inherent nature of the CDMO business, revenues can be uneven across quarters depending on customer schedules, project milestones and commercialisation timelines. Accordingly, business performance is best assessed over a longer period rather than on a quarter-to-quarter basis. • During the quarter, business performance remained resilient, with continued progress across key customer programmes despite a challenging operating environment. • The order book stood at Rs. 137 crore as of 30th September 2026, providing healthy revenue visibility for the coming quarters. • We continue to expand customer engagement across existing and new applications, creating a broader base of opportunities for future business conversion. • Several customer molecules are progressing through different stages of development and commercialisation, with some programmes moving closer to commercial production. This progress has the potential to translate into additional volumes and contribute to future revenue growth. • Based on the current business pipeline, order book and progress across customer programmes, we believe H2 performance is likely to be better than H1. With continued progress across customer programs, increasing penetration across end-use applications and a focus on execution excellence, we remain confident of delivering improved business performance.. Executive Summary Execution Highlights & Growth Drivers • Life Sciences capacity expansion largely remains on track and is expected to enhance our ability to support future customer requirements and growth opportunities. • We are undertaking debottlenecking initiatives across manufacturing facilities, including the installation of downstream equipment, to enhance throughput and increase effective production capacity. • Certain manufacturing facilities underwent planned shutdowns of approximately 10 days during the quarter to facilitate debottlenecking and capacity enhancement activities. • We are pursuing backward integration by developing in-house capabilities for critical raw materials to reduce dependence on China-based sourcing, strengthen supply chain resilience and improve overall margin. • Several yield improvement initiatives are underway to enhance process efficiencies, particularly as production volumes increase, enabling us to become more competitive in larger-volume customer programmes. • We continue to work on adopting new technologies and process innovations to improve existing products, enhance manufacturing capabilities and strengthen our competitive positioning. • We successfully completed two major customer audits during the quarter, one each in Life Sciences and Specialty Chemicals, with no major observations, reaffirming the strength of our quality systems and compliance framework. • We were awarded the EcoVadisGold Rating for the third consecutive year, reflecting our continued commitment to sustainability, responsible business practices and ESG excellence. Strong execution across customer programs, operational improvements and sustainability initiatives continues to strengthen our capabilities and position us for sustained future growth H1 FY27 Financial Performance – Comparative Analysis Revenue EBIDTA PAT 12,000 2,000 1000 823 10,688 1,664 10,000 1,000 0 8,000 -500 -1000 6,000 -1500 2,993 -1,000 4,000 -2000 2,000 -2,000 -2500 -3000 0 -3,000 -2,663 -3500 -3,132 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 EPS Net Worth Borrowings 0.93 1 20,000 12,000 17,174 10,228 0 10,000 15,000 -1 8,000 9,449 -2 10,000 6,000 3,015 -3 4,000 5,000 -4 2,000 -4.15 -5 - - H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 Amount in INR Lakhs, except percentage and EPS 6 Strategic Growth & Business Development Highlights Open Order Book Amount in INR Crores LLiiffee SScciieenncceess SSppeecciiaallttyy CChheemmiiccaallss CCDDMMOO GGrraanndd TToottaall INR ~73 INR ~10 INR ~55 INR ~137 Major orders from USA/EU Strong portfolio and Confirmed requirements based companies, with custom product shared by large global additional orders expected company Key Focus Areas Dedicated focus on Lifesciences and Spec Chem, custom and portfolio products with a defined cadence Effective order execution and scale-up to improve process efficiency and operational excellence Successful completion of several audits could result into improved customer confidence Audit Approvals Profit and Loss Statement Particulars Quarter Ended 6 Months Ended Year Ended 30-Sep-26 30-Jun-26 30 Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from operations 4,755 5,599 1,728 10,353 2,955 10,235 Operating Expenses (4,587) (4,102) (2,838) (8,689) (5.618) (12,677) EBIDTA 168 1,497 (1,110) 1,664 (2,663) (2,442) EBIDTA Margin (%) 4% 27% (64%) 16% (90%) (24%) Depreciation and Amortisation (206) (200) (199) (406) (394) (788) Finance Cost (113) (200) (176) (313) (311) (723) Other Income 315 19 30 334 38 61 Profit/(loss) before exceptional items and tax 164 1,116 (1,454) 1,280 (3,329) (3,892) Exceptional items - - (21) - (22) 82 Profit [Showing first 8,000 characters — download PDF for full document]